Sovereignty ended his racing career with a victory in the October 31 Longines Breeders’ Cup Classic at Keeneland, beating The Puma and Knightsbridge in the championship’s closing race. The win gives sports fans a clear result to celebrate and a new chapter to follow as the colt moves toward the breeding shed.

For cannabis-minded readers, there is also a useful distinction behind the racing spectacle: CBD has its own classification under the sport’s medication rules. Familiarity with human wellness products does not establish what is permitted for a racehorse. Nothing in this report alleges cannabinoid use or a medication violation by any horse or participant named here.

A decisive finish at Keeneland

The Breeders’ Cup’s official recap records Sovereignty’s winning margin as one and three-quarter lengths in the $7 million Classic. Junior Alvarado rode the Godolphin-owned and bred four-year-old for trainer Bill Mott. The Puma finished second, with Knightsbridge third.

The winner completed the mile and a quarter in 2:00.36. The seven-horse field included defending champion Forever Young, who finished fifth. These are the October 31 race results, rather than a preview of a championship still to come. The distinction matters when older entries and pre-race assessments continue circulating after the event.

The race organizer’s account describes Sovereignty’s career as concluding with eight wins from 13 starts. It also marks Mott’s third Classic victory. The result supplies a sporting endpoint; it does not, by itself, establish anything about the medical management of the individual runners.

The next chapter is already identified

Darley’s October 31 announcement says Sovereignty is set to join its stallion roster at Jonabell Farm. It places the Classic alongside a record that includes the Kentucky Derby, Belmont Stakes, Travers and Whitney. The announcement also identifies Knightsbridge as joining Darley America’s stallion ranks in 2027.

That shift changes what followers should watch next. A racing retirement ends one kind of competition, while a stallion announcement concerns a different commercial and breeding role. Neither should be confused with an upcoming race entry or an assurance about the future performance of offspring.

Darley identifies Sovereignty as a son of Into Mischief. The pedigree is part of how a stallion prospect is described, but ancestry should not be mistaken for a prediction. The competitive record belongs to this horse; future offspring will have their own results.

Where CBD fits in racing

The Horseracing Integrity and Welfare Unit’s current substance lookup lists cannabidiol, or CBD, as a controlled substance with HISA status S7 B. That is a specific classification. It should not be casually rewritten as either an unrestricted supplement approval or a claim that CBD belongs to the separate banned-substance category.

The useful lesson is to consult the rulebook governing the animal and competition involved. A product’s availability in a store is a different fact from its status under an anti-doping and medication-control program. Marketing language such as natural or hemp-derived does not answer the regulatory question.

This classification also does not establish that a product is an effective treatment for a particular horse. Competition compliance, veterinary judgment and evidence of clinical benefit are separate questions. A consumer headline cannot provide an individualized medication plan or a safe withdrawal interval.

Labels are only the start of a supplement check

In a May 19 advisory, HIWU explains that it and HISA do not approve, certify or endorse dietary supplements as permitted products. Its lookup searches individual ingredients, rather than supplement brand names. The advisory concerns supplement due diligence generally, not a finding about the Classic field.

HIWU warns that an ingredient missing from the lookup is not automatically permitted, and that a label may not reveal every substance actually present. It directs questions about ingredients to its science team. Those limits make a self-issued clean label an insufficient basis for assuming compliance.

For owners and trainers, the practical step is to work with the appropriate veterinary and regulatory professionals using the current rules and the exact product involved. For fans, it is to avoid treating an unfamiliar substance category as a shortcut to a doping allegation.

Keep the result and the rules in perspective

Our marathon results and CBD coverage makes a related point about sport-specific guidance. The existence of one rule in a human competition does not decide the rules for horses, nor does an athlete’s result disclose what products they use.

Sovereignty’s farewell remains a racing story: a champion won his final start on October 31. The cannabis connection is a separate, factual look at CBD’s place in the sport’s regulatory framework. Following both subjects responsibly means celebrating the verified performance while keeping treatment claims, supplement marketing and compliance questions distinct.

Illustrative racing photograph; not Sovereignty, Alvarado or the 2026 Breeders’ Cup. Photo: @coldbeer / Pexels.

Andreas Almgren won his marathon debut and Sheila Chepkirui reclaimed the women’s title at the November 1 TCS New York City Marathon. The World Athletics results list their winning times as 2:06:01 and 2:24:36, respectively, after a race weekend that brought the running world back to New York.

For cannabis-aware runners following the race, there is also a practical distinction worth keeping clear: enjoying running culture and shopping for a CBD product are different from complying with competition rules. Anti-doping guidance applies to substances, not a product’s wellness branding. Nothing in the race results establishes cannabis use by any of the athletes named here.

The men’s race rewarded a first attempt

Sweden’s Almgren finished 13 seconds ahead of Italy’s Yemaneberhan Crippa, who ran 2:06:14. Kamohelo Mofolo of Lesotho completed the podium in 2:06:26, just one second ahead of fourth-place Benson Kipruto. Those official times show how close the contest remained behind the winner.

The leading American was Zouhair Talbi, sixth in 2:06:43. Ahmed Muhumed placed eighth in 2:07:09, Ryan Ford tenth in 2:07:17 and Conner Mantz eleventh in 2:07:27. For readers scanning beyond the winner, that group gives a fuller picture of the American men’s presence near the front.

New York Road Runners’ post-race account describes Almgren staying with the lead group before making his decisive move with roughly a mile remaining. The organizer says he became the first Swede to win any division at the event. His debut therefore carried significance beyond simply adding another name to the results sheet.

Chepkirui returns to the top

Chepkirui’s 2:24:36 gave the Kenyan another New York victory after her 2024 title. American Jessica McClain finished second in 2:24:42, with Hellen Obiri third in 2:24:43. At the resolution of the published results, six seconds separated first from second and one second separated second from third.

NYRR describes McClain overtaking Obiri in the final meters. It also identifies her finish as the first open-division podium by an American woman at the race since Shalane Flanagan’s third place in 2018. That combination of a returning champion and a late change in podium order gave the women’s race its own distinct story.

In the wheelchair divisions, the organizer reports Swiss victories for Marcel Hug and Catherine Debrunner. Hug’s 1:28:14 extended his event record to eight wins; Debrunner finished in 1:40:02. These are separate competitive divisions, and their results belong alongside the open races in an account of the day.

Why CBD labels do not settle the rules

As runners move from race coverage back to training and product choices, the U.S. Anti-Doping Agency’s CBD guidance offers a relevant cannabis connection. CBD itself is permitted under World Anti-Doping Agency rules, while other cannabinoids remain prohibited in competition. USADA warns that a product sold as CBD can contain other cannabinoids, including THC.

The agency also emphasizes athlete responsibility for substances found in a sample. Third-party certification can reduce contamination risk, but does not eliminate it. A reassuring label is consequently not the same thing as a guarantee that a product is compatible with an athlete’s obligations.

This does not mean every recreational runner faces an identical testing program. It means runners subject to anti-doping requirements need to identify the rules that actually govern them. State retail availability, a friend’s recommendation and a manufacturer’s recovery language answer different questions from the competition’s substance policy.

There is a health question alongside the eligibility question. FDA’s consumer guidance warns that CBD can affect other medicines and cause adverse effects, including changes in alertness. The agency says most retail CBD products have not undergone its evaluation for effectiveness, dosage or interactions. A product clearing one sports-policy question would not resolve those separate issues. Runners should bring the exact product and their medication list to a qualified healthcare professional, rather than infer suitability from a race-weekend advertisement or an elite athlete’s finishing time.

A result is not a recovery study

The performances in New York are evidence of what happened in the race. They are not evidence that CBD improves recovery, that cannabis helps marathon performance or that a particular product is safe for an individual runner. Drawing those conclusions would require different evidence from a finishing table.

Our earlier New York marathon cannabis and CBD guide addressed the race-weekend context. Sunday’s newly available results now add the competitive outcome. The useful next step for fans is to read the newly published official standings; for athletes considering cannabinoid products, it is to check the applicable rules and seek qualified advice about personal health questions.

Illustrative stock running track; not the New York City Marathon road course or race. Photo: KoolShooters / Pexels.

A newly published study in Sports Health puts cannabis conversations inside the training room under scrutiny. The research, first published online October 21, surveyed elite and professional contact-sport athletes and medical or training personnel about cannabinoids. Its central subject is a gap between interest in these products and confidence discussing them.

For cannabis-minded sports readers, this is a useful shift from celebrity anecdotes to the relationship between athletes and the people responsible for their care. The findings concern reported experiences and perceptions. They do not establish that cannabis improves performance or that any particular team has changed its rules.

Read the denominator beside the headline

The study includes 166 athlete respondents and 64 medical or training staff. Participants could skip questions, so the number answering changes across the paper. In the results section, the widely repeated finding that 56 percent currently used cannabis or cannabinoid products is presented in a subsection referring to 105 respondents.

That detail changes how a reader should describe the result. A percentage attached to one survey item should travel with its relevant sample, rather than become a claim about every person who entered the study or about professional sport as a whole. The full paper is more useful than a detached percentage circulating online.

A survey measures reported experience

The authors used anonymous online questionnaires and recruitment through sporting networks, personal contacts and peer sharing. They could not calculate a response rate. Their limitations section identifies self-selection and self-report as concerns, and cautions against generalizing the results or drawing causal conclusions.

In practical terms, people especially interested in cannabis may be more inclined to answer a survey about it. Memories and willingness to disclose can also shape responses. Those possibilities do not erase what participants said; they define the kind of evidence available and the questions a stronger follow-up study would need to address.

Interest and understanding are different measures

The researchers describe educational needs on both sides of the athlete-provider relationship. That is a different finding from demonstrating that a product is effective. Someone can believe a substance helps, want to learn about it and still lack reliable information about its ingredients or possible interactions.

For readers, the useful distinction is between a report of use, a report of perceived benefit and a controlled test of an outcome. A questionnaire can explore the first two. Establishing an effect on recovery, sleep or competition performance requires research designed to evaluate that particular question.

It is also worth separating a request for better communication from an endorsement of a treatment. A clinician can invite an accurate account of what someone takes while continuing to assess evidence, risks and the rules governing that person’s sport. Openness does not require a predetermined answer about a product.

The rulebook still matters

USADA’s cannabinoid guidance explains that CBD is permitted under World Anti-Doping Agency rules, while other cannabinoids are prohibited in competition. It also warns that CBD products can contain prohibited cannabinoids, and that athletes subject to those rules are responsible for substances found in their samples.

That distinction prevents a common shortcut: treating a CBD label as assurance that a finished product is acceptable for competition. The permitted status of one compound does not certify every ingredient in a bottle, gummy or powder. USADA further says third-party certification reduces, but does not eliminate, contamination risk.

Readers should also avoid exporting one framework to every league. The applicable governing body, competition rules and any medical-exemption process need to be identified for the actual athlete. This survey is not a new anti-doping policy, a clearance certificate or permission to ignore a team’s requirements.

What better evidence would look like

A useful next study could make recruitment and item-level samples especially clear, include a broader range of participants and distinguish products and reasons for use. Repeated measurements could examine whether an education program changes knowledge or willingness to talk. A clinical trial would answer a different question about a specified intervention.

Those research tasks should stay separate when the findings enter public discussion. Better disclosure, better information and demonstrated therapeutic outcomes are related interests, but one cannot stand in for all three. The current paper gives sports organizations questions to investigate rather than a universal cannabis prescription.

For fans and participants following the plant’s place in sport, the most useful takeaway is the need for a more precise conversation: which product, which evidence, which rulebook and which person’s circumstances? Keeping those questions visible is more informative than turning a survey percentage into a verdict on cannabis and athletics.

Illustrative stock Pilates studio; not a contact-sport team facility or study location. Photo: Karl Solano / Pexels.